Brief: Endurance RP Says Agreement For Rights To Commercialise Fortacin In Israeli And Balkan Regions
Dec 14 (Reuters) - Endurance RP Ltd 0575.HK :
* AGREEMENT FOR RIGHTS TO COMMERCIALISE FORTACIN IN ISRAELI
AND
BALKAN REGIONS
* UNIT ENTERED INTO AN EXCLUSIVE LICENCE AGREEMENT WITH SK-
PHARMA
Further company coverage: 0575.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regent Pacific
See all newsBrief: Regent Pacific Says SenstendTM Approved By NMPA For Premature Ejaculation In China
Brief: Regent Pacific Says Deep Longevity To Launch U.S. Expansion In Q1 2026
Brief: Regent Pacific Shall Allot And Issue 63.4 Million Shares At Hk$0.485 Per Share
Brief: Regent Pacific Announces Submission Of Senstend New Drug Application To NMPA In China
Brief: Regent Pacific Enters Manufacturing And Supply Agreement For SENSTEND